121 million deaths were recorded worldwide; the most recent occurred in 1968 [2] . Recent studies estimate that influenza infection results in 88,000 hospitalizations and 36,000 deaths per year [3, 4] .
The efficacy of inactivated vaccines against influenza has been demonstrated since the 1940s [5, 6] , and since then vaccination has been the method primarily employed for influenza prevention. Influenza vaccination efforts have focused on persons at increased risk of influenza-related complications and their close contacts, including health care workers. Persons currently recommended for annual vaccination include persons 50 years of age or older, children aged 6-59 months, and persons of any age with certain chronic medical conditions, including those who are HIV infected [7] . In the United States, routine annual influenza vaccination of HIV-infected persons has been recommended by the Advisory Committee on Immunization Practices and the US Public Health Services since the early 1990s [8, 9] . Current guidelines recommend that all HIVinfected patients receive influenza vaccine annually regardless of their immunologic status. Numerous studies have assessed influenza coverage rates among populations at increased risk of influenza-associated complications in the United States [10, 11] . The 2003 National Health Interview Survey (NHIS) estimated vaccination coverage among adults with high-risk conditions aged 18-49 and 50-64 to be 24% and 46%, respectively [12] , well below the Healthy People 2010 goal of 60% [13] . Studies of influenza vaccine coverage in HIV-infected patients conducted during the early 1990s estimated coverage rates of ∼30% [14, 15] . More recent data on the subject have not been published.
The objectives of the present study were to assess trends in annual influenza vaccination coverage in HIV-infected patients during the pre-highly active antiretroviral therapy (HAART) and HAART eras and to determine factors associated with receipt of influenza vaccination.
METHODS

Adult and Adolescent Spectrum of HIV Disease (ASD) project.
We analyzed data collected from medical records of HIV-infected persons observed between 1990 and 2003 in the ASD project, a longitudinal cohort study. The methods used in ASD have been described in detail elsewhere [16] . Information on demographic characteristics, mode of exposure to HIV, clinical and laboratory findings, and treatments were abstracted at selected HIV care facilities from 10 sites: Atlanta, Bayamon (Puerto Rico), Dallas, Denver, Detroit, Houston, Los Angeles, New Orleans, New York City, and Seattle. Clinical data were collected retrospectively for a 1-year period preceding enrollment into ASD and then prospectively at 6-month intervals using a standardized medical records abstraction form until death or the patient's last contact with the ASD facility.
Classification of variables used in our analyses. For our analyses, we defined an influenza season as 1 October to 31 March of each year, starting with 1 October 1990 (the beginning of the 1990 season) and ending with March 2003 (the end of the 2002 season). Because patients with many years of followup could have been vaccinated more than once and contributed to 11 influenza season, we calculated person-seasons to be used as the denominator for our analyses. For any given season, only patients who had medical abstraction forms completed for the entire season were included. Persons whose medical chart documented receipt of influenza vaccine during the season were considered vaccinated. Vaccine coverage was defined as the number of persons with documented influenza vaccinations divided by the number of person-seasons.
Each patient was assigned a single mode of exposure to HIV based on a hierarchy of risks used for HIV surveillance purposes [17, 18] . Persons were defined as having a history of diabetes or pneumonia if either a history or new onset of these conditions was documented in the medical records. Patients were defined as receiving HAART if they were prescribed at least 3 drugs from 2 different antiretroviral drug classes or 3 nuceloside reverse transcriptase inhibitors at any time during the corresponding influenza season. Persons who were prescribed antiretroviral drugs that did not meet the criteria for HAART were defined as receiving antiretroviral therapy (ART) but not HAART.
To categorize HIV load, for each influenza season, we used the value from that season's abstraction form that was closest to the beginning of that season. If this was not available, we used a viral load recorded from the previous abstraction interval or from the last abstraction form during the influenza season. If a viral load was still unavailable, we categorized these persons as having a missing viral load. CD4 T cell count during the interval was calculated by obtaining the mean CD4 T cell count for the influenza season or by substituting the last value from the previous abstraction interval. If a CD4 T cell count was still unavailable, we categorized these persons as having a missing CD4 T cell count.
Statistical methods. We stratified data for the pre- HAART (1990 HAART ( -1995 and HAART (1996 HAART ( -2002 eras. We calculated crude and adjusted odds ratios (AORs) and 95% confidence intervals for receiving influenza vaccination. To identify factors associated with receipt of influenza vaccination, we used multivariate logistic regression with the generalized estimating equations method. We included in our models all available demographic and clinical variables that had been shown in previous studies to be associated with influenza vaccination, as well as those with scientific plausibility of an association with influenza vaccination. The Cochran-Armitage test for trend was used to assess change in annual vaccine coverage over time. SAS (version 9.1; SAS Institute) was used for all statistical analyses.
Because information on health insurance was not collected during the early years of the ASD project, this variable was analyzed only for the HAART era. Likewise, because of the limited availability of antiretroviral drugs and viral load testing in the early 1990s, we limited our analyses of these variables to the HAART era only. Table 1 summarizes the demographic characteristics of 51,021 HIV-infected patients included in these analyses. The majority of patients were male (77%), ethnically diverse (33% white, 43% black, and 18% Hispanic), and born in the United States (71%). Fifty-seven percent of males were infected with HIV through male-to-male sexual contact (MMS); 39% and 31% of females were infected by heterosexual contact and injection drug use (IDU), respectively.
RESULTS
Influenza vaccination coverage for the entire study period was 31%. Vaccination rates increased initially from 28.5% in 1990 to 34% in 1992 and then declined, reaching a low of 21.4% during 1995. Vaccination coverage steadily increased beginning in 1995 and reached a high of 41.6% in 2002 (figure 1). Vaccine coverage varied with CD4 T cell count at the time of vaccination (figure 2). During the pre-HAART era, vaccine coverage was lowest for patients with CD4 T cell counts у500 cells/mL; coverage for those with CD4 T cell counts between 200 and 499 and !200 cells/mL was similar during this period. By contrast, during the HAART era, vaccine coverage for those with CD4 T cell counts of !200 cells/mL was much lower than that for persons with higher CD4 T cell counts. As a result, we chose to stratify the remainder of our analysis using the pre-HAART and HAART time periods.
Results of our analysis for 1990-2002 stratified by HAART era are shown in table 2. In the pre-HAART era, we found that whites, Hispanics, and those whose mode of HIV exposure was blood contact, heterosexual contact, or MMS/IDU were more likely to have received influenza vaccine. Persons with CD4 T cell counts between 200 and 499 cells/mL were more likely to have received influenza vaccine (AOR for CD4 T cell count 200-349 cells/mL, 1.17; AOR for CD4 T cell count 350-499 cells/mL, 1.10), and persons with CD4 T cell counts !200 cells/ mL were equally likely to have received influenza vaccine as those with CD4 T cell counts у500 cells/mL. Persons born in the United States (AOR, 0.75) were less likely to have received vaccine, as were persons missing a CD4 T cell count during the influenza season (AOR, 0.51). During the pre-HAART era, we observed linear increases in influenza vaccination coverage associated with increasing age ( ) and increasing frequency of medical visits during P ! .000001 the season ( ). Persons who had a history of pneu-P ! .000001 monia were less likely to be vaccinated during the pre-HAART era (AOR, 0.93). Having a history of diabetes did not increase the likelihood of influenza vaccination.
Vaccination coverage significantly increased from 29.3% in the pre-HAART era to 32.7% in the HAART era. Vaccination coverage rates in whites increased slightly in the HAART era, whereas the increase in vaccination coverage in blacks was more substantial, increasing from 24.7% to 32%. No change in coverage was seen for Hispanics but for those of "other or unknown" race, vaccine coverage dropped from 33.5% in the pre-HAART era to 28.8% in the HAART era. As a result of these changes, during the HAART era, persons who were Hispanic (AOR, 0.76) or of other/unknown race (AOR, 0.69) were less likely to have received influenza vaccine than blacks. Whites and blacks were equally likely to have received influenza vaccine during this time period. Patients with publicly funded health insurance, other forms of health insurance, and no health insurance or with unknown insurance status were more likely to have received influenza vaccination than those with private health insurance. Persons born in the United States were significantly less likely to be vaccinated than persons who were foreign born (AOR, 0.63) during both the pre-HAART and HAART era. Persons prescribed ART (AOR, 1.5) or HAART (AOR, 1.70) were significantly more likely to have received influenza vaccine. Persons with CD4 T cell counts !200 cells/ mL or viral load у50,000 copies/mL were significantly less likely to have received vaccine. During the HAART era, there were linear increases in influenza vaccine coverage associated with increasing age and frequency of medical visits. Persons who had 2-4 visits and 5 or more visits during the season were almost 4 and 9 times more likely to have received influenza vaccination, respectively, than those with just 1 visit. A steady secular increase was noted in vaccine coverage for each year during the HAART era. In this study population, vaccination coverage reached an all-time high of 41.6% during 2002. No associations were noted between receipt of influenza vaccine and history of diabetes or pneumonia during the HAART era.
DISCUSSION
Because of its size and diversity, ASD provides a unique opportunity to estimate influenza vaccine coverage and determine factors associated with vaccination among HIV-infected people in the United States. Our overall influenza vaccination coverage of 31% was similar to coverage rates of 28% and 33% reported in earlier studies of HIV-infected patients in the United States [14, 15] . Countries with more universal access to health care have reported influenza vaccine coverage rates as high as 92% among their HIV-infected populations [19] .
Our findings are consistent with other US studies that have evaluated vaccination coverage rates in populations not infected with HIV but at increased risk for the complications of influenza. Influenza vaccination coverage rates in 1995 among adults !65 years of age with 1 or more high-risk conditions ranged from 20% in persons aged 18-49 to 38% in persons aged 50-64 years [20] . Coverage rates among persons aged 18-64 years remained low at 32% in 2002 [21] . During 2003, 34% of persons with asthma and 49% of diabetics self-reported that they had received an influenza vaccination that year; vaccine coverage increased with increasing age [22] .
In our cohort, vaccine coverage declined to a low of 21.5% in 1995. Speculation about an association between influenza vaccination and increased HIV load generated by several case reports during the mid to late 1990s was subsequently dismissed but may have had a transient impact on influenza vaccination rates around that time [23, 24] . Vaccine coverage increased steadily starting in 1995 and reached 41.6% during 2002.
During both the pre-HAART and HAART eras, increased vaccination coverage was associated with increasing age, an association that has been noted in several previous studies [14, 20, 25] . Similar to other studies, we also observed a linear increase in vaccine coverage associated with an increasing frequency of medical visits [14, 15, 25, 26] .
Our findings suggest that some variables associated with vaccine coverage changed from the pre-HAART to the HAART eras. Racial disparities affecting blacks during the pre-HAART era had dissipated during the HAART era, although rates in Hispanics did not change.
We noticed that in the pre-HAART era, persons with the highest CD4 T cell counts were least likely to receive influenza vaccination. Although we have no direct evidence, this may have occurred because persons with higher CD4 T cell counts were not perceived to be at increased risk for influenza-associated complications. In the HAART era, persons with CD4 T cell counts !200 cells/mL were significantly less likely to receive vaccination. This may have been an indirect result of studies published in the mid to late 1990s that reported that patients with low CD4 T cell counts were less likely to respond to vaccination [27] [28] [29] .
After controlling for confounders, persons with public insurance, other types of insurance, and no insurance were more likely to receive influenza vaccine than those with private insurance. One study, conducted in The Netherlands, also noted that persons with private health insurance had lower vaccination rates than those with government-provided health insurance [30] . This finding may be explained by differential documentation of vaccination in persons with different types of health insurance or by the fact that private insurance may not include coverage for vaccination.
Finally, persons prescribed antiretroviral drugs were more likely to be vaccinated against influenza, perhaps because they were more likely to access health care or receive better-quality health care. This finding is consistent with a previous analysis of ASD data, which reported a higher rate of influenza vaccination (46%) in persons receiving ART [31] .
Our study has several limitations. First, because medical chart abstraction was conducted only at the ASD location, we may have underascertained true vaccine coverage because vaccine received at other locations may not have been documented in the chart. This underascertainment, if present, appears to be minimal, because our estimates for vaccine coverage in 2002 are similar to self-reported coverage rates seen for other highrisk adults for whom vaccine is recommended. Second, 20% of the patients included in our analysis were from a single ASD site (Atlanta), and almost 17% were from New Orleans. Influenza vaccination practices are likely to vary across different health care facilities. Among the ASD sites, vaccination rates varied widely during the pre-HAART era, from a low of 19% to a high of 43%. In the HAART era, sitespecific vaccination rates ranged from 7% to 41% (authors' unpublished data). Our overall findings may have been influenced by this variation and the imbalanced contribution of patients from different sites. Finally, by design, our cohort includes only patients who are receiving medical care for their HIV infection.
Influenza vaccine is efficacious in the HIV-infected population [32] . Despite increases in vaccine coverage in recent years, substantial gains must occur to ensure protection against seasonal influenza and to meet the Healthy People 2010 goal of 60% coverage. Patient-centered and provider-centered approaches should be combined to increase understanding about influenza, the vaccine, and opportunities for vaccination. Additional research efforts in the HIV-infected population should focus on barriers to and predictors of vaccination in persons receiving routine medical services as well as those who are not in care.
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